Physician profile
Vikash Dugar
NPI 1154541175
$744.00
in general payments reported to CMS, 2019-2025
15 companies · $299 in 2025
The $299 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.75 · 2022: $112 · 2023: $130 · 2024: $184 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $612.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $176.74 | 2022-2025 | Entyvio |
| Medtronic, INC. | $76.12 | 2024 | Intellis Adaptivestim |
| Regeneron Healthcare Solutions, INC. | $61.20 | 2025 | Dupixent |
| Janssen Biotech, INC. | $57.82 | 2023-2024 | Stelara |
| Abbott Laboratories | $52.65 | 2019-2022 | |
| Spr Therapeutics, INC | $49.93 | 2025 | Sprint Pns System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.02 | 2024-2025 | Relistor, Trulance |
| Abbvie INC. | $44.36 | 2023-2024 | Skyrizi, Rinvoq |
| Lilly USA, LLC | $36.06 | 2024-2025 | Omvoh |
| Kowa Pharmaceuticals America, INC. | $29.48 | 2022 | |
| Qol Medical, LLC | $28.68 | 2025 | Sucraid |
| Bioventus LLC | $23.11 | 2022 | |
| Saluda Medical Americas, INC. | $20.96 | 2024 | Evoke |
| Collegium Pharmaceutical, INC. | $20.71 | 2025 | Xtampza |
| Globus Medical, INC. | $17.16 | 2025 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikash Dugar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.